Tetrahydrobiopterin, the cofactor required for hydroxylation of aromatic amino acids regulates its own synthesis in mammals through feedback inhibition of GTP cyclohydrolase I. This mechanism is mediated by a regulatory subunit called GTP cyclohydrolase I feedback regulatory protein (GFRP). The 2.6 A Ê resolution crystal structure of rat GFRP shows that the protein forms a pentamer. This indicates a model for the interaction of mammalian GTP cyclohydrolase I with its regulator, GFRP. Kinetic investigations of human GTP cyclohydrolase I in complex with rat and human GFRP showed similar regulatory effects of both GFRP proteins.
Introduction
GTP cyclohydrolase I (E.C. 3.5.4.16) catalyses the conversion of guanosine triphosphate (GTP) to dihydroneopterin triphosphate (H 2 NTP), the initial and rate limiting step in the de novo synthesis of tetrahydrobiopterin (BH 4 ). BH 4 is an essential cofactor for phenylalanine hydroxylase, tyrosine hydroxylase and tryptophane hydroxylase 1 and can affect the rate of biosynthesis of neurotransmitters such as serotonin or dopamine and hormones like melatonin via its intracellular concentration. Furthermore, BH 4 serves as a cofactor in all three forms of nitric oxide synthase 2 and glycerol ether monooxygenase. 3 As BH 4 , unlike other cofactors, is one of the regulators of these enzymic reactions, 4 it plays an important role in the control of phenylalanine catabolism and of neural and immune functions. Disorders in BH 4 synthesis are associated with serious neuronal diseases such as hyperphenylalaninemia. 5 The intracellular BH 4 concentration is controlled by the rate of its de novo synthesis 1 by GTP cyclohydrolase I through transcriptional 6 and substrate 7 level regulators. Mammalian GTP cyclohydrolase I is subject to feedback inhibition by BH 4 mediated by complex formation with GTP cyclohydrolase I feedback regulatory protein (GFRP). 8 In the presence of GFRP and GTP, BH 4 inhibits GTP cyclohydrolase I while phenylalanine stimulates the enzyme. 9 This mode of GTP cyclohydrolase I regulation provides a mechanism to regulate phenylalanine catabolism and to avoid toxic accumulation of phenylalanine. BH 4 synthesis is also inhibited by various other pterins. The prototypic inhibitor 2,4-diamino-6-hydroxypyrimidine (DAHP) has been shown to act by a dual mechanism, dependent on, and independent of GFRP. 4 However, recent ®ndings indicate, that the regulation of GTP cyclohydrolase I activity might be different in different cell types as no GFRP mRNA was detectable in dopaminergic neurons. 10 It has also been shown that mammalian GTP cyclohydrolase I gets phosphorylated in vivo, 11 and that phoshorylation modulates GTP cyclohydrolase I activity. 12 GFRP has been puri®ed, sequenced and cloned from rat liver. 9 Crosslinking and sedimentation experiments indicate that the 9.5 kDa protein forms a pentamer. 13 Gel ®ltration and enzyme activity measurements indicate that in both the inhibitory and the stimulatory complex the number of GFRP molecules equals that of the GTP cyclohydrolase I monomers. Mammalian GTP cyclohydrolase I forms decameric complexes similar to that of Escherichia coli, 14, 15 suggesting that the regulatory complex consists of a GTP cyclohydrolase I decamer sandwiched between two GFRP pentamers. 16 
Overall structure
The structure of GFRP has been solved and re®ned to a crystallographic R-factor of 16.3 % (R free 21.1 %) in the resolution range of 20-2.6 A Ê by the multiple isomorphous replacement technique using three derivatives. (Table 1 ). The structure has also been solved in a second, cubic crystal form and was re®ned to an R-factor of 21.7 % (R free 26.5 %) showing no signi®cant differences between the two crystal forms. GFRP forms a pentamer of identical subunits ( Figure 1 ). Each subunit consists of all the residues of the rat sequence, with the N-terminal Met being cleaved off post-translationally. A monomer is folded into an a/b-structure with a dominant six-stranded antiparallel b-sheet. Between the strands S2 and S3, a short helix (H1, residues [25] [26] [27] [28] [29] [30] [31] and between the strands S4 and S5 a longer helix (H2, residues 52-60) are inserted. Both helices are located on the same side of the b-sheet. The monomers form a propeller-like pentamer with helix H2 located in the interface between the subunits. The pentamer forms a bent disk with convex and concave surfaces. The approximate dimensions are 50 A Ê Â 50 A Ê Â 20 A Ê . Within the loop connecting S1 and S2, a bound metal ion coordinated to the backbone carbonyl groups of Gln9, Arg11, Val14 and the side-chain oxygen atom of Thr8 with distances of 2.8 A Ê (Gln9), 2.9 A Ê (Arg11) 2.9 A Ê (Val14) and 3.0 A Ê (Thr8) was found. Furthermore, the backbone carbonyl group of Gly15 and a water molecule are 3.5 A Ê away. The coordination can best be described as a distorted, incomplete pentagonal bipyramid. The nature of this ion could not be determined unambiguously, but as no metal apart from potassium could be identi®ed by total re¯ection X-ray¯uorescence, it was modelled as a potassium ion from the crystallisation buffer. Between the strands S3 and S4, the residues 37-44 form a long, yet well-de®ned loop protruding away from the pentamer.
Upon oligomerisation, 34.5 % of the monomer surface is buried. The interface is composed of a mixture of hydrophobic and hydrophilic interactions. The innermost strand of the propeller-like structure, S5 contacts the equivalent strand of the neighbouring monomers and the helix H2 contacts the loop connecting S2 to H1 and His81 at the C terminus.
Proposed complex formation with GTP cyclohydrolase I
The known GFRP sequences are highly homologous ( Figure 2 ), suggesting that interactions between GTP cyclohydrolase I and its regulatory protein are similar in these species. Rat GFRP regulates human GTP cyclohydrolase I as well as a del- 
etion mutant of GTP cyclohydrolase I shortened N-terminally by 41 residues at the same level.
Comparison of the surface potentials of rat GFRP and the recently solved N-terminally shortened mutant of human GTP cyclohydrolase I allow us to speculate about the mode of interaction between the GFRP pentamer and human GTP cyclohydrolase I (Figure 3) . The contact surface of human GTP cyclohydrolase I is mainly positively charged (red colour). The convex surface of GFRP (Figure 3(a) ) is also positively charged while the concave bottom of the pentamer displays a neutral to negative surface potential (Figure 3(c) , blue colour). Therefore the interaction of GFRP with human GTP cyclohydrolase I is likely via its concave side. Docking of GFRP to the GTP cyclohydrolase I structure containing the residues 57-250 of the original human GTP cyclohydrolase I sequence with FTDOCK 17 yielded a model complex with the expected binding mode (Figure 4) . Electrostatic interactions were considered as implemented in FTDOCK, i. e. of the backbone atoms terminal nitrogen and oxygen atoms are asigned a charge of 1 and À1, and peptide nitrogen and oxygen atoms get a charge of 0.5 and À0.5, respectively. Furthermore, charges are asigned to the side-chain atoms Arg-N Z (0.5), Glu-O e (À0.5), Asp-O d (À0.5), Lys-N z (1.0) and Pro-N (À0.1). The above mentioned docking solution was the only biochemically reasonable solution, i. e. with the GFRP-pentamer located on the 5-fold symmetry axis of the cyclohydrolase decamer. Applying varying parameters in FTDOCK no other reasonable complex, most notably no complex with the convex side of GFRP bound to GTP cyclohydrolase I, was found.
In the aforementioned model, the exposed loop between the strands S3 and S4 binds into the cleft formed by two neighbouring cyclohydrolase monomers. All the three non-conservative substitutions of rat GFRP compared to the human sequence do not participate in the proposed binding site, thus supporting an identical regulatory mechanism in rat and man. The bound metal ion is part of the proposed interface, but the functional role, if any, of the metal ion is unclear. Kinetic studies failed to show a dependence of the functional properties on any metal ion. The mutation of Thr8, the only residue coordinating the metal ion via its side-chain, to alanine led to a complete loss of protein expression. This might indicate a role of metal binding in structure stabilisation or protein folding. Regarding the coarseness of such a rigid body docking experiment, we feel that a more detailed discussion of the docked complex in respect of single amino acid side-chain conformations is not appropriate, as it would be a signi®cant overinterpretation of the available data. On the basis of the complex model, we cannot speculate on a possible binding side for phenylalanine.
Regulatory properties of GFRP
To account for possible biochemical differences between the rat and human protein, the rat sequence was mutated to the human sequence. To verify our model of GFRP binding to human GTP cyclohydrolase I, calmodulin-binding peptide (CBP), a 21 amino acid residue C-terminal fragment from muscle myosin light-chain kinase was fused to the N terminus of human GFRP with a linker of 15 amino acid residues. During the puri®-cation process 19 amino acid residues were cleaved off at the N terminus, leaving a 17 amino acid residue CBP-fragment attached to GFRP. As the N termini of the monomers protrude from the top side of the GFRP pentamer, the CBP-linkerfragment should prevent binding to human GTP cyclohydrolase I with this side. Gel ®ltration experiments with the CBP-GFRP fusion protein and human GTP cyclohydrolase I revealed that the GFRP-GTP cyclohydrolase I complex is still formed, supporting the proposed side of complex formation.
Kinetic investigations of human GTP cyclohydrolase I in complex with rat GFRP or human CBP-GFRP showed that both proteins regulate human GTP cyclohydrolase I of the same order of magnitude. Upon addition of BH 4 to a mixture of the respective proteins with GTP, the speci®c activity of human GTP cyclohydrolase I drops from 135 nmol min À1 mg À1 to 3 nmol min À1 mg
À1
in the case of rat GFRP and from 85 nmol min À1 mg À1 to 7 nmol min À1 mg À1 in the case of the human CBP-GFRP fusion protein. To strengthen our arguments further, hisactophilin, a 119 amino acid residue protein from Dictyostelium discoideum was fused to the N terminus of human GFRP. The resulting fusion protein showed regulatory effects of the same order of magnitude as the CBP-GFRP fusion protein.
As the GTP-binding sites of human GTP cyclohydrolase I lie approximately 30 A Ê away from the potential GFRP-binding site (Figure 4 ) and the phenylalanine-binding sites are still unknown, the precise regulatory mechanism requires further investigation.
Structural homologues
A search for related structures with the program DALI 18 did not reveal biologically signi®cant structural homologies. Only three structures with a Zscore 53 were reported; the closest homologue with a Z-score of 3.8 is E. coli YciH (PDB entry 1D1R), a putative translation initiation factor.
Materials and Methods

Protein expression and purification
The cDNA for the rat GFRP was cloned by reverse transcriptase polymerase chain reaction yielding a PCR product of 255 bp encompassing the open reading frame. The ampli®cate was ligated into pQE7 (Quiagen) and expressed in E. coli XL1. The recombinant GFRP was puri®ed in a three-step procedure by heat precipitation (72 C) followed by anion exchange chromatography (QSepharose), the column was washed with buffer A containing 50 mM Tris-HCl and 2 mM dithioerythritol (DTE) and developed with a linear gradient of 0 to 500 mM KCl in buffer A. As ®nal puri®cation step the protein was applied to a gel ®ltration coloumn (Superdex 75 C, Pharmacia) and eluted with 100 mM potassium phosphate, 2 mM DTE (pH 7.4). The rat sequence was mutated to the human sequence by PCR and puri®ed as described. Calmodulin-binding peptide and hisactophilin were fused to the N-terminus of the human sequence in pNCO and expressed in E. coli XL1-Blue cells. The CBP-GFRP fusion protein was puri®ed by cation exchange chromatography (Sepharose SP Fast Flow) with 50 mM potassium phosphate (pH 7.5), 2 mM DTE as equilibration buffer and 50 mM potassium phosphate (pH 7.5), 2 mM DTE, 1 M KCl as elution buffer. The hisactophilin-GFRP fusion protein was puri®ed by nickel af®nity chromatography with 20 mM Tris (pH 8.0), 500 mM NaCl, 10 mM b-mercaptoethanol (ME) as equilibration buffer and 20 mM Tris (pH 8.0), 500 mM NaCl, 500 mM imidazole, 10 mM b-ME as elution buffer.
The reaction mixture for the determination of GTP cyclohydrolase I activity 19 contained 50 mM Tris-HCl (pH 7.5), 1 mM GTP and recombinant GTP cyclohydrolase I. The reaction mixture for the complex contained 50 mM Tris-HCl (pH 7.5), 1 mM GTP, 400 mM BH4, recombinant GTP cyclohydrolase I and GFRP. The samples were incubated at 37 C and absorbance at 330 nm was recorded. The concentration of 7,8-dihydroneopterin triphosphate was estimated using the absorption coef®cient of e 6300 M
À1
.
Total reflection X-ray fluoresence
Total re¯ection X-ray¯uoresence using a Atomica (Oberschleiûheim, Germany) spectrometer was applied to investigate the nature of the bound ion. Protein solution (5 ml of 5 mg/ml in 100 mM potassium phosphate (pH 7.5)) that was puri®ed as described above were used to measure X-ray¯uoresence. No metal ion apart from potassium could be identi®ed in any of the measurements.
Crystallisation and data collection GFRP was crystallised in a batch procedure. The recombinant protein was concentrated in the gel ®l-tration buffer (100 mM potassium phosphate, 2 mM dithiothreitol (pH 7.4)) up to 5 mg/ml. Crystallisation was observed at 4 C overnight and produced long needles with dimensions 0. Crystal Structure of GFRP equipped with a Rigaku mirror system. A second crystal form (space group I2 1 3, cell axis 146.6 A Ê ) was obtained from 2 M sodium/potassium phosphate, 0.2 M ammonium sulphate, 0.2 M Hepes and diffracted to 3.0 A Ê .
Structure determination and refinement
All data were evaluated with DENZO 20 and CCP4 programs. 21 The R sym on intensities is 11.8. Multiple isomorphous replacement was used for phase determination by locating heavy-atom sites through difference Patterson methods. Heavy-atom derivatives were prepared by soaking crystals in the mother liquid at 4 C with either 2 mM thiomersal for 48 hours, 1 mM KAu(CN) 2 for 24 hours, or 1 mM K 2 Pt(NO 2 ) 2 (NH 3 ) 2 for 24 hours and interpreted with the PROTEIN program package. 22 Heavy-atom parameters were re®ned with SHARP 23 and the resulting electron density was solvent attened with SOLOMON. 24 Optimisation of local symmetry operators, cyclic averaging and model building was done with MAIN, 25 further re®nement was done with CNS. 26 The data of the orthorhombic crystal form were re®ned to an R-factor of 16.3 % (R free 21.1 %). The r.m.s. deviations from ideal stereochemistry are 0.007 A Ê for bond lengths and 1.38 for bond angles. R free 27 was calculated using 5 % of the re¯ections. The stereochemistry of the model was veri®ed using PROCHECK. 28 The dihedral angles of the polypeptide backbone are all located within allowed regions of the Ramachandran diagram. 29 The cubic crystal form was solved by molecular replacement and re®ned to an R-factor of 21.7 % (R free 26.5 %) with r.m.s. deviations from ideal stereochemistry of 0.011 A Ê for bond lengths and 1.63 for bond angles. Figures were prepared using the programs MOLSCRIPT, 30 Raster3D 31 and ALSCRIPT. 32 Electrostatic potentials were calculated with Grasp. 33 
Protein Data Bank accession code
The coordinates and structure factors have been deposited with the RCSB Protein Data Bank under the accession code 1JG5.
